Lead Sponsor

Novartis

Collaborators

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•• Symptoms of OAB for at least six months prior to randomization
•* ≥ 8 micturitions on average/24 hours
•* ≥ 1 urgency episodes on average/24 hours
•* with or without UUIE
•* Patients dissatisfied with prior oxybutynin ER or tolterodine ER treatment. Patients must have been on either treatment for at least 1 week and up to 12 months preceding this study. It is required that either oxybutynin ER or tolterodine ER was the most recent OAB medication taken.
•* Patients without prior darifenacin treatment

•• A mean daily urinary volume \>3000 mL or a mean volume voided/micturition of \>300 mL as verified in the micturition diary for two consecutive days prior to Baseline
•* Males with post-void residual (PVR) urinary volume \>200 mL at Baseline
•* Clinically predominant and bothersome stress urinary incontinence, as determined by the investigator
•* Urinary retention or clinically significant bladder outlet obstruction as determined by the investigator